Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease
Not Applicable
Terminated
- Conditions
- Kidney DiseaseVascular Disease
- Registration Number
- NCT00638222
- Lead Sponsor
- University of Toledo Health Science Campus
- Brief Summary
Evaluate effectiveness of Carvedilol CR on Micro T-Wave Alternans in high risk hypertensives
- Detailed Description
The effect of Carvedilol CR on Micro T-Wave Alternans will be assessed in 30 hypertensives with stage 4 or 5 chronic kidney disease utilizing a cross-over design and contrasting no treatment against active treatment periods of 8 weeks.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Adults age 18 and older
- Chronic kidney disease
- Must be able to do stress test
Exclusion Criteria
- Must not be mentally disabled
- Unable to provide informed consent
- Unable or unwilling to comply with study protocol or procedures
- Pregnancy or unknown pregnancy status in female of childbearing potential
- Participation in any drug trial during the study period
- Prior enrollment in this study
- Active liver disease
- Currently on β-blocker medication at the time of enrollment
- Known history of asthma exacerbation with β-blocker therapy
- Second or third degree AV nodal block or bradycardia with resting heart rate <50 bpm
- Prior allograft organ transplantation
- Planned allograft transplantation reasonably foreseen within the active treatment period
- Electrocardiographic left or right bundle branch block
- Permanent implanted pacemaker
- Atrial fibrillation
- Ongoing treatment with any of the following medications: sotalol (Betapace), azimilide (Stedicor), quinidine (Quinidex), disopyramide (Norpace), dofetilide (Tikosyn), ibutilide (Corvert), procainamide (Procanbid), bepridil (Vascor), amiodarone (Cordarone), clarithromycin (Biaxin), erythromycin (Eryc), halofantrine (Halfan), pentamidine (Pentam), sparfloxacin (Zagam), domperidone (Motilium), droperidol (Inapsine), chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), thioridazine (Mellaril), pimozide (Orap), arsenic trioxide (Trisenox), cisapride (Propulsid), lidoflazine (Clinium), and methadone (Dolophine)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Micro T- Wave Alternans week 1, 8, 11, 18
- Secondary Outcome Measures
Name Time Method Interleukin-6 week 1, 8, 11, 18 Plasma C-reactive Protein week 1, 8, 11, 18 Plasma Cardiac Troponin T week 1, 8, 11, 18 Plasma NT-pro BNP week 1, 8, 11, 18 Plasma F2-isoprostanes week 1, 8, 11, 18 Oxidized LDL week 1, 8, 11, 18
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Carvedilol CR's impact on Micro T-Wave Alternans in chronic kidney disease patients?
How does Carvedilol CR compare to other beta-blockers in managing cardiovascular risk for stage 4/5 CKD hypertensives?
Which biomarkers correlate with Carvedilol CR efficacy in reducing Micro T-Wave Alternans in vascular disease patients?
What adverse events are associated with Carvedilol CR use in patients with comorbid hypertension and chronic kidney disease?
Are there combination therapies involving Carvedilol CR that improve outcomes for CKD-related cardiac arrhythmias?
Trial Locations
- Locations (2)
University of Toledo, Health Science Campus
🇺🇸Toledo, Ohio, United States
Site Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
University of Toledo, Health Science Campus🇺🇸Toledo, Ohio, United States